ReviewActa neurologica Belgica2026
Psychological resilience predicts medication adherence in multiple sclerosis.
Review in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSustained adherence to disease-modifying therapies is essential for preventing relapses and long-term disability progression in people with relapsing-remitting-multiple sclerosis (PwRRMS). Although psychological distress is associated with poor adherence, the independent contribution of psychological resilience remains unclear. This study aimed to determine whether psychological resilience is independently associated with medication adherence (MA) in PwRRMS who are in remission after accounting for psychological distress, disability level, quality of life (QoL), and clinical factors.
methodsThis study included 165 PwRRMS in clinical remission. MA was assessed using the Medication Adherence Report Scale. Psychological resilience, psychological distress, coping attitudes, and QoL were measured using validated scales, and neurological disability was evaluated using the Expanded Disability Status Scale (EDSS). A multivariate logistic regression analysis was conducted after adjusting for depression, anxiety, stress, coping strategies, QoL, EDSS, and disease duration.
resultsCompared with poorly adherent participants, those with good adherence reported (60%) significantly higher resilience, lower depression, anxiety and stress symptoms, and better QoL (all p ≤ .01). Adherence was positively associated with resilience and negatively associated with psychological distress. Regression analysis revealed psychological resilience was the only independent predictor of good adherence (p = .016), whereas psychological distress, QoL, and disability level were not retained.
conclusionsPsychological resilience appears to be a key psychological resource supporting sustained treatment adherence in RRMS, independent of emotional distress, disability severity, or QoL. Routine clinical care may benefit from screening for resilience and the incorporation of resilience-enhancing strategies to improve long-term adherence and optimize patient outcomes.
Indexed as
Identifiers
42207459What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.